stoxline Quote Chart Rank Option Currency Glossary
  
IDEAYA Biosciences, Inc. (IDYA)
27.4  -2.96 (-9.75%)    11-17 16:00
Open: 30.26
High: 30.64
Volume: 2,044,657
  
Pre. Close: 30.36
Low: 26.7
Market Cap: 2,649(M)
Technical analysis
2026-11-17 4:36:26 PM
Short term     
Mid term     
Targets 6-month :  38.15 1-year :  42.45
Resists First :  32.66 Second :  36.34
Pivot price 31.57
Supports First :  26.7 Second :  22.21
MAs MA(5) :  30.75 MA(20) :  32.31
MA(100) :  36.33 MA(250) :  34.01
MACD MACD :  -1.5 Signal :  -1.3
%K %D K(14,3) :  14.8 D(3) :  20.6
RSI RSI(14): 29
52-week High :  42.68 Low :  26.7
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ IDYA ] has closed below the lower bollinger band by 24.1%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 6.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 30.68 - 30.87 30.87 - 31
Low: 26.29 - 26.51 26.51 - 26.66
Close: 27.11 - 27.43 27.43 - 27.66
Company Description

IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.

Headline News

Tue, 17 Nov 2026
IDEAYA Biosciences, Inc. (IDYA) Stock Price, News, Quote & History - Yahoo! Finance Canada

Tue, 17 Nov 2026
Is IDEAYA Biosciences (IDYA) Undervalued After Its FDA Backed IDE849 Trial Plan? - Yahoo Finance Singapore

Tue, 17 Nov 2026
Ideaya Biosciences: Staying Bullish On Darovasertib NDA Submission And More (NASDAQ:IDYA) - Seeking Alpha

Mon, 16 Nov 2026
IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas - PR Newswire

Sun, 15 Nov 2026
Ideaya picks cancer drug candidate, targets human trial application in 2027 (IDYA:NASDAQ) - Seeking Alpha

Fri, 13 Nov 2026
IDYA - IDEAYA Biosciences, Inc. | News - OTC Markets

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 97 (M)
Held by Insiders 9.084e+007 (%)
Held by Institutions 2.1 (%)
Shares Short 9,930 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -4.6032e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 343.7 %
Return on Equity (ttm) -24.2 %
Qtrly Rev. Growth 3.654e+007 %
Gross Profit (p.s.) -1188.75
Sales Per Share -480.75
EBITDA (p.s.) -4.70062e+009
Qtrly Earnings Growth -4.5 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -347 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.06
Price to Cash Flow 0.19
Stock Dividends
Dividend 0
Forward Dividend 9.08e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

Stoxline iOS

Alpha Bridge iOS

OptionCalc iOS

StockChart Android

Stoxline Android

Alpha Bridge Android

OptionCalc Android